Increasing expression of miR-5100 in non-small-cell lung cancer and correlation with prognosis.
A previous study indicated that miR-5100 served as a tumor oncogene in lung cancer. However, whether miR-5100 may serve as a novel prognostic marker in non-small cell lung cancer (NSCLC), has not been investigated. The aim of this study was to investigate miR-5100 expression and its clinical significance in NSCLC patients. Expression of miR-5100 was detected in NSCLC tissues and matched normal lung tissues by quantitative Real-time polymerase chain reaction. The correlation between miR-5100 expression and clinical features were statistically analyzed. Survival rate was analyzed by log-rank test, and survival curves were plotted according to Kaplan-Meier. The correlation between miR-5100 expression and prognosis of NSCLC patients was further evaluated by univariate and multivariate analysis. As revealed by qRT-PCR analysis, the relative level of miR-5100 expression in NSCLC tissues was significantly upregulated, compared with that in corresponding noncancerous tissues (p < 0.01). Additionally, high miR-5100 expression was statistically associated with higher clinical stage (p < 0.001), N classification (p = 0.003) and M classification (p = 0.027), but lower differentiated degree (p < 0.001). Furthermore, the results of Kaplan-Meier suggested that NSCLC patients with higher miR-5100 expression had significantly poorer overall survival (p < 0.0001) and progression-free survival (p < 0.0001). Multivariate survival analysis verified that miR-5100 expression level was an independent predictor of both overall survival and progression-free survival for NSCLC patients. Our data suggested that up-regulation of miR-5100 was correlated with NSCLC progression, which provided a potential prognostic biomarker and therapeutic target.